[8-K] FRACTYL HEALTH, INC. Reports Material Event

Rhea-AI Filing Summary

Fractyl Health, Inc. entered into an underwriting agreement with BofA Securities, Inc. and Evercore Group L.L.C. to sell 60 million shares of its common stock at $1.00 per share in an underwritten offering pursuant to an effective Form S-3 shelf registration. The company estimates net proceeds of approximately $56.0 million after underwriting discounts, commissions and estimated offering expenses. The closing is expected on September 29, 2025, subject to customary closing conditions. The filing references related exhibits including the Underwriting Agreement, legal opinion and consent of counsel, a press release dated September 26, 2025, and embedded cover page XBRL tags.

Insights

Financial Analyst

TL;DR: The company is raising roughly $56M via a 60M share offering at $1.00, which provides near-term liquidity but increases share count.

This transaction supplies Fractyl Health with immediate capital that can fund operations or development without waiting for operating cash flow. The offering price of $1.00 and resulting 60 million share issuance will expand the equity base and is likely dilutive to existing shareholders unless offset by material value creation from the use of proceeds. The net proceeds estimate is explicit at $56.0 million, and closing is contingent on customary conditions with an expected date of September 29, 2025. Underwriters named are BofA Securities and Evercore, which may facilitate distribution efficiency.

Corporate Governance Expert

TL;DR: The filing documents a standard underwritten equity raise with supporting legal opinions and exhibits; shareholders should note scope of issuance.

The 8-K includes the Underwriting Agreement and counsel opinion exhibits, indicating customary legal and disclosure procedures were followed. The filing shows transparency by attaching the press release and cover page XBRL. The material action is the public issuance of 60 million shares at a stated price of $1.00, with estimated net proceeds of $56.0 million. From a governance perspective, the company has disclosed relevant documents and the expected closing date, but the filing does not specify intended use of proceeds or effects on outstanding share count.

false 0001572616 0001572616 2025-09-26 2025-09-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 26, 2025

Fractyl Health, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-41942		27-3553477
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
3 Van de Graaff Drive Suite 200
Burlington, Massachusetts				01803
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (781) 902-8800

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value per share		GUTS		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On September 26, 2025, Fractyl Health, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc. and Evercore Group L.L.C., as representatives of the several underwriters set forth therein (collectively, the “Underwriters”), to issue and sell 60 million shares of common stock of the Company, par value $0.00001 per share (“Common Stock”), in an underwritten offering (the “Offering”) pursuant to an effective shelf registration statement on Form S-3 (File No. 333-285522) (the “Registration Statement”) and a related prospectus and prospectus supplement, in each case filed with the Securities and Exchange Commission (the “SEC”). The offering price is $1.00 per share of Common Stock, less underwriting discounts and commissions. The Company estimates that the net proceeds from the Offering will be approximately $56.0 million after deducting underwriting discounts and commissions and estimated offering expenses. The closing of the Offering is expected to occur on September 29, 2025, subject to customary closing conditions.

The Company believes that the net proceeds from the Offering, together with its existing cash and cash equivalents, will be sufficient to enable the Company to fund its operating expenses and capital expenditure requirements into early 2027.

The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties.

A copy of the Underwriting Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K, and is incorporated herein by reference. The foregoing description of the Underwriting Agreement is qualified in its entirety by reference to such exhibit. A copy of the opinion of Cooley LLP as to the legality of the issuance and sale of the securities in the Offering and related consent is filed as Exhibit 5.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

On September 26, 2025, the Company issued a press release announcing that it had priced the Offering. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished with this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act or the Exchange Act.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the Offering, such as the expected net proceeds and anticipated closing date and the Company’s expected cash runway. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding the Company’s business are described in detail in its SEC filings, including in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements except as may be required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
1.1		Underwriting Agreement by and between Fractyl Health, Inc, BofA Securities, Inc. and Evercore Group L.L.C., dated September 26, 2025.
5.1		Opinion of Cooley LLP.
23.1		Consent of Cooley LLP (included in Exhibit 5.1).
99.1		Press Release, dated September 26, 2025.
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Fractyl Health, Inc.
Date: September 26, 2025				By:		/s/ Harith Rajagopalan
						Harith Rajagopalan, M.D., Ph.D. Co-Founder, Chief Executive Officer and Director (Principal Executive Officer)